论文部分内容阅读
几种作为抗肿瘤制剂的重组DNA蛋白,包括肿瘤坏死因子(TNF)、β、γ于扰素及白细胞介素2(IL-2)用于临床试验后,开始出现临床结果。日本Dainippon药厂的重组TNF以不同的途径给予,结果肿瘤内注射的22例病人中10例部分有效或更好的效果,而4例胸腔内注射病人中3例出现同样疗效。用静脉注射或静脉滴注的21例病人中,1例部分有效,1例稍有效。天然的TNF和α-干扰素合用与重组TNF的临床效果相似。在所有TNF临床试验
Several of the recombinant DNA proteins used as antitumor agents, including tumor necrosis factor (TNF), beta, gamma interferon, and interleukin 2 (IL-2), began to show clinical results after clinical trials. The recombinant TNF of Dainippon Pharmaceutical Co., Japan was administered in different ways. As a result, 10 out of the 22 intratumoral injections were partially effective or better, while 3 out of 4 intrapleural injections had the same effect. Of the 21 patients who received intravenous or intravenous infusions, 1 was partially effective and 1 was slightly effective. The combined effects of natural TNF and alpha-interferon are similar to those of recombinant TNF. In all TNF clinical trials